Effect of phytoneering remedy BNO 2103 on the course of experimental exudative inflammation caused by different phlogogens
DOI:
https://doi.org/10.14739/2310-1210.2022.1.237675Keywords:
BNO 2103, herbal composition, anti-inflammatory properties, phytotherapy, preclinical studyAbstract
Kidney and urinary tract diseases play an important role in the disease distribution in most countries of the world. The pharmaceutical industry offers many means for the treatment and prevention of these diseases, but there is a trending tendency to pay more attention to herbal medicines, their empirical application and scientific study.
The aim of this research is to study anti-inflammatory properties of standardized herbal composition BNO 2103 in a model of paw inflammation in rats caused by different phlogogens to justify the use of it in the treatment of chronic kidney disease (CKD).
Materials and methods. The experimental study was performed using 90 male white outbreed rats weighing 150–200 g, which were divided into 3 series of 30 animals each, each series included 3 groups. Inflammation of the paw was induced by subplantar administration of phlogogens – zymosan, histamine and serotonin. The study agent and the reference drug, diclofenac sodium, were administered intragastrically (i. g.) once. Edema was observed and recorded, and anti-inflammatory activity (AIA) was assessed in 0.5, 1.0, 2.0, 3.0 and 6.0 hours after phlogogen injection.
Results. BNO 2103 showed a remarkable anti-exudative effect in the model of zymosan and histamine edema, being significantly superior to diclofenac sodium. In the serotonin edema model, BNO 2103 was significantly superior to the comparator by the endpoints, showing the moderate but prolonged anti-exudative effect.
Conclusions. BNO 2103 has the significant anti-inflammatory effect, exerting an inhibitory effect on exudative inflammation caused by various phlogogens (zymosan, histamine, serotonin), mainly acting on the lipoxygenase pathway of arachidonic acid conversion, which is most likely due to the presence of flavonoids. This allows us to consider BNO 2103 as a promising drug for the treatment of CKD.
References
Höller, M., Steindl, H., Abramov-Sommariva, D., Wagenlehner, F., Naber, K. G., & Kostev, K. (2021). Treatment of Urinary Tract Infections with Canephron® in Germany: A Retrospective Database Analysis. Antibiotics, 10(6), Article 685. https://doi.org/10.3390/antibiotics10060685
Rechberger, E., Rechberger, T., Wawrysiuk, S., Miotla, P., Kulik-Rechberger, B., Kuszka, A., & Wróbel, A. (2021). Randomizovane klinichne vyprobuvannia dlia otsiniuvannia efektyvnosti Kanefronu n porivniano iz tsyprofloksatsynom dlia profilaktyky pisliaoperatsiinykh infektsii nyzhnikh sechovykh shliakhiv pislia operatsii zi vstanovlennia suburetralnoho slinha [Randomized Clinical Trial to Evaluate the Effect of Canephron N in Comparison to Ciprofloxacin in the Prevention of Postoperative Lower Urinary Tract Infections after Midurethral Sling Surgery]. Zdorov'e muzhchiny, (3), 43-48. https://doi.org/10.30841/2307-5090.4.2020.225599 [in Ukrainian].
Kanefron® H (Canephron® N). (n.d.). Kompendyum OnLine. https://compendium.com.ua/dec/269484/
Sivak, K. V., Lesiovskaya, E. E., Stosman, K. I., & Savateeva-Lubimova, T. N. (2016). Efficiency of Canephron N in complex treatment of experimental heymann glomerulonephritis. Clinical Phytoscience, 2(1), Article 5. https://doi.org/10.1186/s40816-016-0021-8
GBD Chronic Kidney Disease Collaboration. (2020). Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 395(10225), 709-733. https://doi.org/10.1016/S0140-6736(20)30045-3
Canadian Council on Animal Care. (n.d.). General Guidelines. Ccac.ca. https://ccac.ca/en/standards/guidelines/general-guidelines.html
Suckow, M., Hankenson, F. C., Wilson, R., & Foley, P. (Eds.). (2019). The Laboratory Rat (3rd ed.). Academic Press. https://doi.org/10.1016/C2017-0-01188-6
EUR-Lex. (2010). Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Europa.eu. https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32010L0063
Altman, R., Bosch, B., Brune, K., Patrignani, P., & Young, C. (2015). Advances in NSAID Development: Evolution of Diclofenac Products Using Pharmaceutical Technology. Drugs, 75(8), 859-877. https://doi.org/10.1007/s40265-015-0392-z
Vogel, H. G. (Ed.). (2008). Drug Discovery and Evaluation (3rd ed). Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-70995-4
Sigidin, Ya. A., Shvartz, G. Ya., Liberman, S. S., & Arzamastsev, A. P. (1988). Lekarstvennaya terapiya vospalitel'nogo protsessa (eksperimental'naya i klinicheskaya farmakologiya protivovospalitel'nykh preparatov) [Drug therapy of inflammatory process (Experimental and clinical pharmacology of antiinflammatory drugs)]. Meditsina. [in Russian].
U.S. Food and Drug Administration. (2005, July 6). Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. U.S. Food and Drug Administration. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers
Stefanov, A. V. (Ed.). (2001). Doklinichni doslidzhennia likarskykh zasobiv [Preclinical studies of drugs]. Avitsena. [in Ukrainian].
Islam, M. A., & Al-Shiha, A. (2018). Foundations of Biostatistics. Springer Singapore. https://doi.org/10.1007/978-981-10-8627-4
Vitkovskyy, V. F. (2021). Efficacy of an herbal preparation based on lovage, rosemary, and centaury on patients after extracorporal shockwave lithotripsy. Clinical Phytoscience, 7(1), Article 10. https://doi.org/10.1186/s40816-021-00247-7
Ma, Z., Lu, Y., Yang, F., Li, S., He, X., Gao, Y., Zhang, G., Ren, E., Wang, Y., & Kang, X. (2020). Rosmarinic acid exerts a neuroprotective effect on spinal cord injury by suppressing oxidative stress and inflammation via modulating the Nrf2/HO-1 and TLR4/NF-κB pathways. Toxicology and Applied Pharmacology, 397, Article 115014. https://doi.org/10.1016/j.taap.2020.115014
Colica, C., Di Renzo, L., Aiello, V., De Lorenzo, A., & Abenavoli, L. (2018). Rosmarinic Acid as Potential Anti-Inflammatory Agent. Reviews on Recent Clinical Trials, 13(4), 240-242. https://doi.org/10.2174/157488711304180911095818
Petrović, S. (2019). Herbal and traditional Herbal Medicinal Products, EU Herbal monographs and EU list. Arhiv Za Farmaciju, 69(4), 221-269. https://doi.org/10.5937/arhfarm1904221p
Nausch, B., Röhrl, J., Koeberle, A., Harler, U., Joannidis, M., Werz, O., & Künstle, G. (2017). 138 - Canephron N reduced immune cell recruitment in experimental cystitis. European Urology Supplements, 16(3), e230-e231. https://doi.org/10.1016/s1569-9056(17)30204-x
Wagenlehner, Florian M., Abramov-Sommariva, D., Höller, M., Steindl, H., & Naber, Kurt G. (2018). Non-Antibiotic Herbal Therapy (BNO 1045) versus Antibiotic Therapy (Fosfomycin Trometamol) for the Treatment of Acute Lower Uncomplicated Urinary Tract Infections in Women: A Double-Blind, Parallel-Group, Randomized, Multicentre, Non-Inferiority Phase III Trial. Urologia Internationalis, 101(3), 327-336. https://doi.org/10.1159/000493368
Nausch, B., Pace, S., Pein, H., Koeberle, A., Rossi, A., Künstle, G., & Werz, O. (2019). The standardized herbal combination BNO 2103 contained in Canephron® N alleviates inflammatory pain in experimental cystitis and prostatitis. Phytomedicine, 60, Article 152987. https://doi.org/10.1016/j.phymed.2019.152987
Künstle, G., Brenneis, C., & Haunschild, J. (2013). 671 Efficacy of Canephron® N against bacterial adhesion, inflammation and bladder hyperactivity. European Urology Supplements, 12(1), e671. https://doi.org/10.1016/s1569-9056(13)61153-7
Dlin, V. V., Abramov-Sommariva, D., Zakharova, I. N., Erman, M. V., Nastausheva, T. L., Kirillov, V. I., Averyanova, N. I., Derevyanko, T. I., Letifov, G. M., Vyalkova, A. A., Margieva, T. V., Morozov, S. L., & Kolchenko, I. I. (2018). A non-interventional, prospective, multicenter study for evaluation of the use of the herbal medicinal product Canephron® N in the pediatric outpatient population in Russia. Clinical Phytoscience, 4(1), Article 31. https://doi.org/10.1186/s40816-018-0092-9
Gorpynchenko, I. I., & Spiridonenko, V. V. (2017). Effektivnost' fitoterapii na fone primeneniyaekstrakorporal'noi udarno-volnovoi terapii u lits s khronicheskim kal'kuleznym prostatitom [The effectiveness of phytotherapy against the backq-ground of the use of extracorporeal shock wave therapyin persons with chronic calculous prostatitis]. Zdorov'e muzhchiny, (2), 20-24. https://doi.org/10.30841/2307-5090.2(61).2017.115926 [in Russian].
Shebeko, S. K., Chernykh, V. V., & Zupanets, K. O. (2020). Nephroprotective Effect of the Herbal Composition BNO 2103 in Rats with Renal Failure. Scientia Pharmaceutica, 88(4), Article 47. https://doi.org/10.3390/scipharm88040047
Downloads
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
